Liver Injury Clinical Trial
Official title:
A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients
The goal of this observational study is to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury. The main questions it aims to answer are: - Exploring risk factors for liver injury. - Constructing a Predictive Model for the Occurrence of Liver Injury in PD-1/PD-L1 Inhibitor-Related Liver Injury. - Improving immunotherapy protocols for lung cancer patients.
PD-1/PD-L1 inhibitors have achieved surprising results in lung cancer treatment and have been approved by the FDA for the treatment of different types of lung cancer. Their overall toxicity is lower than that of standard chemotherapy, but a number of immune-related adverse events have been reported clinically. Liver injury is one of the leading causes of death from adverse events due to PD-1/PD-L1 inhibitors. The occurrence of immune-related liver damage has an important impact on the tumor treatment and prognosis of patients. Most of the current domestic and international studies focus on the overall description and study of PD-1/PD-L1 antibody-related adverse events, and there is no definitive description of the risk factors for the development of immune-related liver injury in lung cancer patients. The aim of this project is to review the clinical data of lung cancer patients treated with PD-1/PD-L1 inhibitors from 2020.01 to 2024.06, to investigate the risk factors of PD-1/PD-L1 inhibitor-associated liver injury, to construct a prediction model for the occurrence of liver injury, and to take measures to prevent the occurrence of fatal immune liver injury, which is of great significance to the immunotherapy of clinical tumor patients. It is of great significance to the immunotherapy of clinical tumor patients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06244550 -
Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors
|
N/A | |
Completed |
NCT01089426 -
Omegaven Treatment of Parenteral Nutrition (PN) Induced Liver Injury
|
N/A | |
Recruiting |
NCT05229328 -
Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
|
||
Recruiting |
NCT06080308 -
Liver Ischemia-reperfusion Injury and Clinical Data Analysis
|
||
Recruiting |
NCT05155358 -
Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke
|
||
Terminated |
NCT04004884 -
Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA)
|
||
Recruiting |
NCT01802996 -
Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury
|
Phase 4 | |
Active, not recruiting |
NCT05882214 -
Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink
|
N/A | |
Completed |
NCT04934384 -
The Role of Prehospital eFAST in Accelerating Time to Diagnostics or Definitive Treatment in the Emergency Department
|
||
Recruiting |
NCT03039062 -
Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy
|
N/A | |
Completed |
NCT00694499 -
Non-Operative Management of High Grade Blunt Hepatic Injury: Clinical Complications and the Role of Collateral Damage
|
N/A | |
Recruiting |
NCT04937868 -
Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients
|
||
Completed |
NCT06249646 -
Contained Hepatic Vascular Injuries Following Liver Trauma
|
||
Terminated |
NCT02915081 -
Blue Light Therapy for Liver Surgery
|
N/A | |
Completed |
NCT03667157 -
Liver Function After Intravenous Methylprednisolone Administration
|
Phase 4 | |
Completed |
NCT03281265 -
A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China
|
N/A | |
Completed |
NCT04257240 -
Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury
|
||
Not yet recruiting |
NCT02808299 -
Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection
|
N/A | |
Not yet recruiting |
NCT06258525 -
SAMe in Prevention of Oxaliplatin-associated Liver Injury
|
Phase 2 | |
Active, not recruiting |
NCT06298318 -
Metabolic Changes in Healthy Subjects With Acute Binge Drink
|
N/A |